Recently, the Office of Talent Work Leading Group of the CPC Shanghai Pudong New Area Committee awarded  the honorary certificates and trophies to the  members of the “Pearl Leading Talent” team who were selected as the “Pearl Elite Talent” in 2024 in Pudong New Area.

Dr. Yan Shuang, as the new drug discovery and translational medicine leader of Leadingtac's Targeted Protein Degradation Project, has successfully passed the rigorous evaluation of the Talent Expert Group of the Pudong New Area Committee under the strong recommendation of Dr. Yan Feng, a Pearl Leading Talent, by virtue of his profound overseas background, rich experience in the R&D of new drugs, and excellent scientific research achievements. She was successfully selected as one of the “Pearl Elite Talent” in Pudong New Area in 2024. This honor is not only an affirmation of her personal research ability and the importance of her team, but also a recognition of Leadingtac's team's R&D capability and project achievements.

About "Pearl Talent Plan":

The "Pearl Plan" is a special policy to support the development of four types of strategic scientific and technological talents by focusing on the major tasks of building a leading area for the construction of socialist modernization and a high-level talent highland, relying on national laboratories, high-level research universities, national scientific research institutes, and scientific and technological leading enterprises, introducing globally a group of high-level overseas talents, who already stood at the international scientific and technological frontiers and led the independent innovation of science and technology, discovering and cultivating a group of innovative and entrepreneurial talents with leading roles or high growth potentials, focusing on the three major pioneering industries and other key industries, and keeping in view the cultivation of new racetracks.

bout Leadingtac:

Leadingtac is a clinical-stage biopharmaceutical company based in Zhangjiang, Shanghai. The company is founded in 2019, dedicated to First-in-class/Best-in-class small molecule innovative drug discovery and development, focusing on autoimmune and oncology, two disease areas with many unmet clinical needs, with Targeted Protein Degradation (TPD) drug discovery and development technology at its core business.  Leadingtac currently has a laboratory and office area of about 2,000 square meters, with 20 formal employees and has completed three rounds of funding since its establishment.